Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
News > Health News
Audio By Carbonatix
4:05 PM on Thursday, December 19, 2024
The Associated Press
SAN DIEGO--(BUSINESS WIRE)--Dec 19, 2024--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time.
A live webcast of Acadia’s presentation will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.
View source version on businesswire.com:https://www.businesswire.com/news/home/20241219997230/en/
CONTACT: Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL GENERAL HEALTH HEALTH MENTAL HEALTH CLINICAL TRIALS
SOURCE: Acadia Pharmaceuticals
Copyright Business Wire 2024.
PUB: 12/19/2024 04:05 PM/DISC: 12/19/2024 04:04 PM
http://www.businesswire.com/news/home/20241219997230/en
